| 臺大學術典藏 |
2021-09-04T06:11:17Z |
Faldaprevir, pegylated interferon, and ribavirin for treatment-na?ve HCV genotype-1: Pooled analysis of two phase 3 trials
|
Jensen D.M.; Asselah T.; Dieterich D.; Foster G.R.; Sulkowski M.S.; Zeuzem S.; Mantry P.; Yoshida E.M.; Moreno C.; Ouzan D.; Wright M.; Morano L.E.; Buynak R.; Bourli?re M.; Hassanein T.; Nishiguchi S.; JIA-HORNG KAO; Omata M.; Paik S.W.; Wong D.K.; Tam E.; Kaita K.; Victor Feinman S.; Stern J.O.; Scherer J.; Quinson A.-M.; Voss F.; Gallivan J.-P.; B?cher W.O.; Ferenci P. |
| 臺大學術典藏 |
2021-09-04T06:11:02Z |
Urgency to treat patients with chronic hepatitis C in Asia
|
JIA-HORNG KAO; Ahn S.H.; Chien R.-N.; Cho M.; Chuang W.-L.; Jeong S.-H.; Liu C.-H.; Paik S.-W. |
| 臺大學術典藏 |
2021-09-04T05:17:13Z |
Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1
|
JIA-HORNG KAO; Yu M.-L.; Peng C.-Y.; Heo J.; Chu C.-J.; Chang T.-T.; Lee Y.-J.; Hu T.-H.; Yoon K.T.; Paik S.W.; Lim Y.S.; Ahn S.H.; Isakov V.; McPhee F.; Hu W.; Scott Swenson E.; Yin P.D.; Treitel M. |
| 臺大學術典藏 |
2021-09-01T01:53:51Z |
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)
|
Park J.-W.; Amarapurkar D.; Chao Y.; Chen P.-J.; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:44Z |
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study
|
Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; Hsu C.-H.; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Avi?a J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:42Z |
Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel
|
ANN-LII CHENG; Amarapurkar D.; Chao Y.; Chen P.-J.; Geschwind J.-F.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Park J.-W. |
| 臺大學術典藏 |
2021-07-03T03:34:19Z |
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)
|
Park J.-W.; Amarapurkar D.; Chao Y.; PEI-JER CHEN; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:14Z |
Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel
|
Cheng A.L.; Amarapurkar D.; Chao Y.; PEI-JER CHEN; Geschwind J.-F.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Park J.-W. |
| 臺大學術典藏 |
2021-05-24T07:20:31Z |
Urgency to treat patients with chronic hepatitis C in Asia
|
Kao J.-H.; Ahn S.H.; Chien R.-N.; Cho M.; Chuang W.-L.; Jeong S.-H.; CHEN-HUA LIU; Paik S.-W. |
| 臺大學術典藏 |
2018-09-10T18:03:52Z |
Urgency to treat patients with chronic hepatitis C in Asia
|
Kao, J.-H.;Ahn, S.H.;Chien, R.-N.;Cho, M.;Chuang, W.-L.;Jeong, S.-H.;Liu, C.-H.;Paik, S.-W.; CHEN-HUA LIU; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T18:03:51Z |
Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1
|
Kao, J.-H.;Yu, M.-L.;Peng, C.-Y.;Heo, J.;Chu, C.-J.;Chang, T.-T.;Lee, Y.-J.;Hu, T.-H.;Yoon, K.T.;Paik, S.W.;Lim, Y.S.;Ahn, S.H.;Isakov, V.;Mcphee, F.;Hu, W.;Scott Swenson, E.;Yin, P.D.;Treitel, M.; JIA-HORNG KAO |
